Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Rating) have been given a consensus recommendation of “Buy” by the five ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $29.50.
A number of research analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of EyePoint Pharmaceuticals in a research report on Friday, March 4th. StockNews.com assumed coverage on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research raised shares of EyePoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, January 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $24.00 target price on shares of EyePoint Pharmaceuticals in a research report on Friday, March 4th.
Institutional investors have recently modified their holdings of the business. Citigroup Inc. grew its position in EyePoint Pharmaceuticals by 139.6% during the 3rd quarter. Citigroup Inc. now owns 2,410 shares of the company’s stock worth $25,000 after purchasing an additional 1,404 shares during the last quarter. FourThought Financial LLC purchased a new position in EyePoint Pharmaceuticals during the 4th quarter worth $28,000. Paragon Capital Management Ltd purchased a new position in EyePoint Pharmaceuticals during the 4th quarter worth $30,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in EyePoint Pharmaceuticals during the 1st quarter worth $30,000. Finally, Point72 Hong Kong Ltd purchased a new position in EyePoint Pharmaceuticals during the 4th quarter worth $36,000. 70.85% of the stock is currently owned by institutional investors.
EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) last announced its quarterly earnings data on Thursday, March 3rd. The company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.09). EyePoint Pharmaceuticals had a negative net margin of 159.70% and a negative return on equity of 46.76%. The firm had revenue of $11.19 million during the quarter, compared to analyst estimates of $9.75 million. During the same quarter in the previous year, the business posted ($1.01) earnings per share. Equities research analysts expect that EyePoint Pharmaceuticals will post -2.64 earnings per share for the current fiscal year.
About EyePoint Pharmaceuticals (Get Rating)
EyePoint Pharmaceuticals, Inc, a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.
- Get a free copy of the StockNews.com research report on EyePoint Pharmaceuticals (EYPT)
- The Sherwin-Williams Company Bottoms Above Institutional Support
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
- Whirlpool Is A Steal At These Prices
- Kimberly-Clark Pops On Successful Price Pass-Through
Receive News & Ratings for EyePoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EyePoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.